Clinical trial · Interventional
Clinico-biological Data Collection Study of Metastatic Lung Cancer
Prediction in Silico of Therapeutic Response in a Prospective Cohort Study of Metastatic Lung Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective database dedicated to patients with breast cancers that contains clinical data as well as epidemiological, psychological, emotional, social, imaging, biological and biopathological data. These data will allow a creation of new modelling algorithms in order to predict response and resistance to treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metastasis biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Follow
- description
- At each disease progression, patient will have specific interventions : * Metastasis biopsy * Biomarkers blood, urine and microbiota samples * Patient Reported Outcome (PRO)
- interventionNames
- Procedure: Metastasis biopsy
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 15 years
- description
- Overall Survival is defined by the delay between the date of inclusion and the date of death or last follow-up assessment
Secondary outcomes (2)
- measure
- To describe response to treatment for each therapeutic sequence
- timeFrame
- 15 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening biopsy, blood sample and questionnaires * 18 years old at time of written consent * Patient with histologically confirmed lung cancer * Lung cancer metastatic disease or locally advanced not eligible for local curative treatment intent * Performance status ≤ 2 (according to WHO criteria) * Indication of any systemic therapeutic strategy can be performed alongside this current cohort in accordance with national and / or international recommendations. * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. * Patient must be affiliated to a Social Health Insurance Exclusion Criteria: * Other malignancy treated within the last 3 years (except non-melanoma skin cancer or in situ carcinoma of the cervix) * Other neuroendocrine tumour than small cell or large cell carcinoma. * Pregnant or nursing patient * Individual deprived of liberty or placed under the authority of a tutor * Impossibility to submit to the medical follow-up of this clinical trial for geographical, social or psychological reasons
References
Publications (0)
Data not yet available